Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

548 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group. Scher HI, et al. Among authors: kantoff p. J Clin Oncol. 2008 Mar 1;26(7):1148-59. doi: 10.1200/JCO.2007.12.4487. J Clin Oncol. 2008. PMID: 18309951 Free PMC article.
Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.
Bajorin DF, Nichols CR, Schmoll HJ, Kantoff PW, Bokemeyer C, Demetri GD, Einhorn LH, Bosl GJ. Bajorin DF, et al. Among authors: kantoff pw. J Clin Oncol. 1995 Jan;13(1):79-86. doi: 10.1200/JCO.1995.13.1.79. J Clin Oncol. 1995. PMID: 7799046 Clinical Trial.
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.
Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Scher HI, et al. Among authors: kantoff p. J Clin Oncol. 2004 Feb 1;22(3):537-56. doi: 10.1200/JCO.2004.07.099. J Clin Oncol. 2004. PMID: 14752077
Bone directed therapies for prostate cancer.
Bradley DA, Hussain M, Dipaola RS, Kantoff P. Bradley DA, et al. Among authors: kantoff p. J Urol. 2007 Sep;178(3 Pt 2):S42-8. doi: 10.1016/j.juro.2007.04.035. Epub 2007 Jul 20. J Urol. 2007. PMID: 17644119 Review.
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.
Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. Morris MJ, et al. Among authors: kantoff p. Clin Genitourin Cancer. 2009 Jan;7(1):51-7. doi: 10.3816/CGC.2009.n.009. Clin Genitourin Cancer. 2009. PMID: 19213669 Free PMC article.
Testicular cancer. Clinical practice guidelines.
Motzer RJ, Bahnson RR, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA; National Comprehensive Cancer Network. Motzer RJ, et al. Among authors: kantoff p. J Natl Compr Canc Netw. 2005 Jan;3(1):52-76. J Natl Compr Canc Netw. 2005. PMID: 19813323 No abstract available.
Kidney cancer. Clinical practice guidelines.
Motzer RJ, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pili R, Pohar KS, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA; National Comprehensive Cancer Network. Motzer RJ, et al. Among authors: kantoff p. J Natl Compr Canc Netw. 2005 Jan;3(1):84-93. J Natl Compr Canc Netw. 2005. PMID: 19813325 No abstract available.
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. Ryan CJ, et al. Among authors: kantoff p. J Clin Oncol. 2010 Mar 20;28(9):1481-8. doi: 10.1200/JCO.2009.24.1281. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159824 Free PMC article. Clinical Trial.
548 results